Literature DB >> 11825572

DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection.

Douglas S Kwon1, Glenn Gregorio, Natacha Bitton, Wayne A Hendrickson, Dan R Littman.   

Abstract

Fusion of the human immunodeficiency virus (HIV) to the plasma membrane of target cells is mediated by interaction of its envelope glycoprotein, gp120, with CD4 and appropriate chemokine receptors. gp120 additionally binds to DC-SIGN, a C-type lectin expressed on immature dendritic cells. This interaction does not result in viral fusion, but instead contributes to enhanced infection in trans of target cells that express CD4 and chemokine receptors. Here we show that DC-SIGN mediates rapid internalization of intact HIV into a low pH nonlysosomal compartment. Internalized virus retains competence to infect target cells. Removal of the DC-SIGN cytoplasmic tail reduced viral uptake and abrogated the trans-enhancement of T cell infection. We propose that HIV binds to DC-SIGN to gain access to an intracellular compartment that contributes to augmentation or retention of viral infectivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825572     DOI: 10.1016/s1074-7613(02)00259-5

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  213 in total

Review 1.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

2.  Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes.

Authors:  Evelyne Schaeffer; Vanessa B Soros; Warner C Greene
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Authors:  Thomas J Ketas; Ines Frank; Per Johan Klasse; Brian M Sullivan; Jason P Gardner; Catherine Spenlehauer; Mirjana Nesin; William C Olson; John P Moore; Melissa Pope
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.

Authors:  Cinzia Nobile; Arnaud Moris; Françoise Porrot; Nathalie Sol-Foulon; Olivier Schwartz
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 6.  Dangerous liaisons at the virological synapse.

Authors:  Vincent Piguet; Quentin Sattentau
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

Review 7.  DC-SIGN: binding receptor for HCV?

Authors:  Zhi-Hua Feng; Quan-Chu Wang; Qing-He Nie; Zhan-Sheng Jia; Yong-Xin Zhou
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

8.  Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.

Authors:  Lakshmanan Ganesh; Kwanyee Leung; Karin Loré; Reuven Levin; Amos Panet; Owen Schwartz; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Authors:  Gurvinder Kaur; Michael Tuen; Diana Virland; Sandra Cohen; Narinder K Mehra; Christian Münz; Sayed Abdelwahab; Alfredo Garzino-Demo; Catarina E Hioe
Journal:  Virology       Date:  2007-09-04       Impact factor: 3.616

10.  Site-specific labeling of enveloped viruses with quantum dots for single virus tracking.

Authors:  Kye-Il Joo; Yuning Lei; Chi-Lin Lee; Jonathon Lo; Jiansong Xie; Sarah F Hamm-Alvarez; Pin Wang
Journal:  ACS Nano       Date:  2008-08       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.